Through the acquisition of Norwegian company Diatec, Curida takes the first steps into biological production.
The acquisition strengthens the base on which Curida aims to grow further in the international CDMO market, it states. Before the acquisition, Curida provides manufacturing and development services out of two sites in Norway, and exports to more than 80 countries.
“Through the acquisition of Diatec we add a highly competent team and new capabilities in modern biological production of pharmaceuticals. Biological manufacturing processes are behind many of the recent advances in pharmaceuticals and vaccines, and the growth potential is enormous,” says Curida CEO, Leif Rune Skymoen.
The capabilities acquired with Diatec allows Curida to enter new partnerships with biotech and pharma companies, from early phase and all the way to the market.
Diatec, which following the acquisition will be named Curida Diatec, has 35 employees and R&D and manufacturing facilities in Oslo.
“We are very happy to become part of an ambitious Norwegian company. Curida has been successful in building a position both nationally and internationally. We look forward to joining forces with Curida and contributing to further growth and development,” says Bjørn K. Pedersen, founder and Managing Director of Diatec.
Curida was established in 2015 through an employee and management buyout of the former Takeda Nycomed site in Elverum. Curida is owned by management and employees along with Norwegian investors Canica, Stokke Industri and Klaveness Marine, as well the governmental investment fund Investinor.
Photo of Leif Rune Skymoen, CEO, Curida